Barda-cbrn-BAA-11-100-SOL-00009

Added: Sep 25, 2013 3:39 pm The purpose of this contract to MRI Global is to conduct advanced development of PCR-based assays for the presumptive diagnosis of anthrax, plague, and tularemia using instrument platforms widely fielded in clinical laboratories. The system will address a major gap in the nation's ability to rapidly diagnose individuals suspected of being infected with Category A bacterial threat agents.

Added: Jun 24, 2013 5:33 pm The purpose of this announcement is for the award of a Cost Sharing/Cost Plus Fixed Fee type contract to Basilea Pharmaceutica International, Ltd. for the Research and Development of BAL30072, a novel monosulfactam for the treatment of infections caused by multi-drug resistant gram-negative bacterial pathogens.

Added: Oct 18, 2012 8:46 am The purpose of this contract is to develop a product that will combine the wound healing properties of the Celution System, which has been developed by the contractor, with a cell-friendly dressing as a medical countermeasure for use in the context of combined injury and radiation exposure, and to obtain FDA licensure for the Celution System with indications for use that explicitly include thermal burn.

Added: Oct 11, 2012 1:13 pm This announcement is for the award of a Cost Plus Fixed Fee (CPFF) type R&D contract to Velico Medical, Inc. for the development of a system to spray dry plasma, under the procedures of the subject Broad Agency Announcement (BAA).

Added: Feb 22, 2012 3:13 pm Slides for the Jan 23 2012 Pre-Proposal Conference for the Thermal Burn amendment to this soliciation.

Added: Feb 03, 2012 10:45 am Thermal Burn Special Instructions

Added: May 18, 2011 1:52 pm Modified: May 20, 2011 10:34 amTrack Changes  BARDA-CBRN-BAA-11-100-SOL-00009

Added: May 18, 2011 1:52 pm  

Added: Feb 18, 2011 4:59 pm BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of CBRN agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the PHEMCE Implementation Plan for CBRN Threats. The Implementation Plan is located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.

In addition, the Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote (i) innovations in technologies that may assist countermeasure and product advanced research and development (ii) research on and development of research tools and other devices and technologies and (iii) research to promote strategic initiations. The PAHPA is also located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.

The purpose of this BAA is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I.

Research Areas of Interest:

1. Vaccines Development
2. Antitoxins and Therapeutics
3. Antimicrobials and Antivirals
4. Radiological and Nuclear Agent Countermeasures
5. Chemical Agent Countermeasures
6. Diagnostics

BARDA anticipates that research and development activities awarded from this Broad Agency Announcement (BAA) will serve to advance the knowledge and scientific understanding of candidates' countermeasures for CBRN threats toward eventual FDA approval and their inclusion in the Strategic National Stockpile (SNS).

The Government intends to have a full & open competition for this requirement in the form of a BAA. This synopsis is not a BAA; a BAA is anticipated on March 4, 2011. The Government expects to make 1 or more awards, subject to the availability of funds, on or about September 16, 2011.

Contact Information:

Comments to this announcement, referencing synopsis BARDA-CBRN-BAA-11-100-SOL-00009 may be submitted to CBRN-BAA-11@hhs.gov

Pre-proposal Conference:

A pre-proposal conference will be held on March 23rd, 2011 from 2-4 pm at the following address:

200 Independence Avenue S.W.
Hubert H Humphrey Building 7th floor Room 725A
Washington, DC 20201

Please note the following regarding the pre-proposal conference:

1. Enter the Humphrey Building at the Independence Avenue Street entrance.
2. Arrive 30 minutes early to allow time to clear security.
3. Bring a state-issued form of identification.*
4. The closest metro stop is Federal Center SW
5. Attendance is limited to a maximum of two (2) people per company. Email the names of your attendees to CBRN-BAA-11@hhs.gov by Friday, March 11, 2011.
6. Tape recorders and videos are prohibited.
7. Presentation material from the conference will be posted on FedBizOpps in an amendment to the BAA following the pre-proposal conference

* Be advised that in order to obtain security clearance, advanced notification must be provided by all attendees who are not United States citizens.

Pre-proposal Conference #2: A second pre-proposal conference is anticipated on or about June 8, 2011 in San Diego, CA and will be announced in a subsequent FedBizOpps amendment to this BAA.

Questions from industry regarding the Special Instruction B (announced in a subsequent FedBizOpps amendment) may be emailed to CBRN-BAA@hhs.gov no later than March 15, 2011. Submitted questions will be addressed during the March 23rd Pre-Proposal Conference.

NOTE: For those unable to attend, you may choose to dial-in and still participate in the conference. Please notify us of your interest in this option and use the following dial-in information: 1-800-369-2101 Participant code # 45746.